Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen?;Place actuelle des inhibiteurs de l'aromatase dans le traitement adjuvant des cancers du sein. Reste-t-il des indications aux anti-œstrogènes de type tamoxifène ?

Presse Medicale

Volumn 36, Issue 2 II, 2007, Pages 333-340

  Bergerat, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ARTHRALGIA; AXILLARY LYMPH NODE; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; COGNITION; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DYSPAREUNIA; ENDOMETRIAL DISEASE; FOLLOW UP; HUMAN; INSOMNIA; LIBIDO DISORDER; MEMORY; POSTMENOPAUSE; SHORT SURVEY; THROMBOEMBOLISM; VAGINAL DRYNESS; ADJUVANT CHEMOTHERAPY; AMENORRHEA; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; MENSTRUATION; MORTALITY; PATHOLOGY; REVIEW;

AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MENSTRUATION; POSTMENOPAUSE; TAMOXIFEN;

EID: 34047159962     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2006.12.019     Document Type: Short Survey

References (51)

1. Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Bushnell C.D., and Goldstein L.B. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63 (2004) 1230-1233
3. Geiger A.M., Fischer G.M., Chen W., and Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 96 (2004) 1528-1536
4. Howell A., Curick J., Baum M., Buzdor A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
5. The A.T.A.C. Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamosifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
6. Thurlimann B., Keshaviah A., Coates A.J., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
7. Monnier A. The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98. Breast 15 1 Suppl (2006) 21-29
8. Coombes R.C., Hall E., Gibson L.J., Paridaens L., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
9. Jakesz R., Jonat W., Gnant M., Mittlboecko M., Greil R., Tausch G., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
10. Boccardo F., Rubagotti A., Guglielmini P., Fini A., Paledini G., Mesiti M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17 Suppl 7 (2006) vii10-vii14
11. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart J.M., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
12. Jakesz R., Samonigg H., and Greil R. Extended adjuvant treatment with anastrozole : results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a. Proc Am Soc Clin Oncol 23 (2005) 10s
13. Coombes R.C., Paridaens R.C., Jassem J., Van De Velde D.J., Delozier T., et al. First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24 (2006) LBA527
14. Jonat W., Gnant M., and Boccardo F. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer : a meta-analysis of the ARNO 95 trial, ABCSG trial8, and the ITA trial. Br Cancer Res Treat. 94 suppl 1 (2005) 10
15. Whelan T.J., Goss P.E., Ingle J.N., Pater J.L., Tu D., Pritchard K., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 (2005) 6931-6940
16. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 24 6 (2006) 910-917
17. Cuzick J., Sasieni P., and Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 94 (2006) 460-464
18. Hilsenbeck S.G., and Osborne C.K. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res 12 (2006) 1049s-1055s
19. Punglia R.S., Kuntz K.M., Winer E.P., Weeks J.C., and Burstein H.J. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23 (2005) 5178-5187
20. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
21. Delozier T., Spielmann M., Janvier M., Fourquet A., Veyret C., Weber B., et al. Optimal duration of adjuvant tamoxifen in early breast cancer : ten year results or a randomized trial of the FNCLCC Breast Group. Breast Cancer Res and Treatment 94 suppl 1 (2005) (abs 14)
22. Ingle J.N., Tu D., Pater J.L., Martino S., Robert N.J., Muss H.B., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99 (2006) 295-300
23. Goss P.E. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 33 Suppl 7 (2006) S8-S12
24. Tralongo P., Di Mari A., and Ferrau F. Cognitive impairment, aromatase inhibitors, and age. J Clin Oncol 23 18 (2005) 42-43
25. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
26. Regan M.M., and Gelber R.D. Predicting response to systemic treatments: learning from the past to plan for the future. Breast 14 (2005) 582-593
27. Bardou V.J., Arpino G., Elledge C.R., Osborne C.R., and CLark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21 (2003) 1973-1979
28. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
29. Viale G., Regan M., Dell'Orto P., Del Curto B., Braye S., Orosz Z., et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res and Treatment 94 suppl 1 (2005) (abs 44)
30. Osborne C.K., Schiff R., Arpino G., Lee A.S., and Hilsenberg V.G. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14 (2005) 458-465
31. Cui X., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 (2005) 7721-7735
32. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97 (2005) 1254-1261
33. Osborne C.K., Shou J., Massarweh S., and Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11 (2005) 865s-870s
34. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
35. Gee J.M., Robertson J.F., Gutteridge E., Ellis I.O., Pinder S.E., Rubini M., et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12 Suppl 1 (2005) S99-S111
36. Normanno N., Di Maio M., De Maio E., De Luca A., Mattis A., Giordano A., et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12 (2005) 721-747
37. De Laurentiis M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11 (2005) 4741-4748
38. Dowsett M., Ebbs S.R., Dixon J.M., Skena A., Griffith C., Boeddinghauss I., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol 23 (2005) 2477-2492
39. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cusssac A., Janicke F., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
40. Berry D.A., Muss H.B., Thor A.D., Dressler L., Liu E.T., Broadwater G., et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18 (2000) 3471-3479
41. Knoop A.S., Bentzen S.M., Mielsen M.M., Rasmussen B.B., and Rose C. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19 (2001) 3376-3384
42. De Placido S., De Laurentiis M.N., Carlomagno C., Gallo C., Perrone F., Pepe S., et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9 (2003) 1039-1046
43. Stal O., Fern O.M., Kallstom A.C., Malmstrom P., and Nordenskjork B. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11 (2000) 1545-1550
44. Argiris A., Wang C.X., Whalen S.G., and DiGiovanna M.P. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10 (2004) 1409-1420
45. Rocchi A., and Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14 (2006) 917-927
46. Cameron D.A., Kerr G., Jack W., Bowman A., Kunkler I., Dixon M., et al. Does everyone need letrozole after 5 years' tamoxifen and breast conservation. Breast Cancer Res and Treatment 88 suppl 1 (2004) (abs 108)
47. Finn R.S., Dering J., Ginther C., Press M., Forbes J., Mackey J., et al. ER+ PR- breast cancer defines a unique subtype of breast cancer tahat is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Am Soc Clin Oncol (2006) (abs 514)
48. Johnston S.R., Martin L.A., and Dowsett M. Life following aromatase inhibitors--where now for endocrine sequencing?. Breast Cancer Res Treat 93 Suppl 1 (2005) S19-S25
49. Martin L.A., Pancholi S., Chan C.M., Farner I., Kimberley C., Dowsett M., et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 12 (2005) 1017-1036
50. Dowsett M., Nicholson R.I., and Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93 Suppl 1 (2005) S11-S18
51. Dowsett M., Smith A., Skene A., Llombart A., Mayordomo J.I., Detre S., et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenoapusal women, with ER/PgR+ breast cancer (Study 223). Am Soc Clin Oncol (2006) (abs 515)